SCHEMBL30984013

SCHEMBL30984013

Cc1ccnc(Cn2c(-c3ccc(Br)cc3Cl)nc3c(Cl)ncnc32)c1

nearest known ligand 0.34

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ CNR1 P21554 5/20 0.34
▸ KCNH2 Q12809 3/20 0.34
▸ NPC1 O15118 1/20 0.34
▸ RAB9A P51151 1/20 0.34
▸ SMN1; SMN2 Q16637 1/20 0.34
▸ L3MBTL1 Q9Y468 1/20 0.34
▸ HSP90B1 P14625 2/20 0.33
▸ PDE10A Q9Y233 1/20 0.33
▸ TRAP1 Q12931 1/20 0.32
▸ MEN1 O00255 2/20 0.32
▸ KMT2A Q03164 2/20 0.32
▸ SCN5A Q14524 1/20 0.32
▸ SCN9A Q15858 1/20 0.32
▸ CRHR1 P34998 1/20 0.31
▸ PIK3CD O00329 1/20 0.30
▸ FBP1 P09467 1/20 0.30
▸ NR2F2 P24468 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30983829 0.83 KCNH2 (0.34) CNR1KCNH2PDE10ASCN5ASCN9A
SCHEMBL30984047 0.79 CNR1 (0.44) CNR1PDE10AMEN1KMT2ANR2F2
SCHEMBL30983809 0.77 TLR7 (0.38) CNR1KCNH2SMN1; SMN2
SCHEMBL30983808 0.72 CNR1 (0.32) CNR1KCNH2MEN1KMT2AFBP1
SCHEMBL30983779 0.72 KCNH2 (0.36) CNR1KCNH2SCN5ASCN9APIK3CD
SCHEMBL31269215 0.72 KCNH2 (0.34) CNR1KCNH2MEN1KMT2ASCN5A
SCHEMBL30984004 0.71 KCNH2 (0.32) KCNH2SCN5ASCN9APIK3CD
SCHEMBL31269054 0.70 KCNH2 (0.34) CNR1KCNH2PDE10ASCN5ASCN9A
SCHEMBL30983784 0.68 PIK3CD (0.40) CNR1PDE10AMEN1KMT2APIK3CD
SCHEMBL30983966 0.65 MEN1 (0.46) NPC1RAB9ASMN1; SMN2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4689155-A1 USE OF INHIBITORS TO INCREASE EFFICIENCY OF CRISPR/CAS INSERTIONS Astrazeneca AB (SE) 2026-02-11 — — EP disclosed
EP-4630410-A1 POLQ INHIBITORS Astrazeneca AB (SE) 2025-10-15 — — EP disclosed
WO-2024201368-A1 USE OF INHIBITORS TO INCREASE EFFICIENCY OF CRISPR/CAS INSERTIONS ASTRAZENECA AB (SE) 2024-10-03 — — WO disclosed
WO-2024121753-A1 POLQ INHIBITORS ASTRAZENECA AB (SE) 2024-06-13 — — WO disclosed
Send feedback